It is a second-generation sulfonylurea oral hypoglycemic drug. Its main mechanism of action is to promote endogenous insulin secretion. It takes effect 30 minutes after oral administration and lasts for about 16-24 hours.

It is an oral biguanide hypoglycemic drug that reduces blood sugar levels by reducing liver glucose output and increasing peripheral tissue absorption of glucose. It can promote endogenous insulin secretion, reduce fat synthesis, maintain or reduce body weight, and thus reduce the risk factors of arteriosclerosis.

It has a chemical reaction that neutralizes or buffers the gastric acid already in the stomach, covers the inner wall of the stomach and duodenum to protect it, and can absorb free acid; it has astringent and hemostatic effects with the aluminum chloride produced by gastric acid.

It has an antacid effect and can be used together with aluminum hydroxide to correct the constipation and abdominal distension caused by the use of aluminum hydroxide alone.

It is a defoaming agent that can change the surface tension of bubbles and cause them to burst, thereby eliminating bubbles in the gastrointestinal tract.

This product is an imidazole antifungal drug that has an inhibitory or killing effect on Candida fungi, and its mechanism of action is still unclear.

Tetracycline antibiotics. This product is a broad-spectrum antibacterial agent with bactericidal effects at high concentrations. Rickettsia, Mycoplasma, Chlamydia, atypical mycobacteria, and spirochetes are also sensitive to this product. This product is more effective against Gram-positive bacteria than Gram-negative bacteria, but Enterococcus is resistant to it. Others such as Actinomycetes, Bacillus anthracis, Listeria monocytogenes, Clostridium, Nocardia, Vibrio, Brucella, Campylobacter, and Yersinia are sensitive to this product. This product has certain antibacterial activity against Neisseria gonorrhoeae, but penicillin-resistant Neisseria gonorrhoeae is also resistant to doxycycline. Due to the widespread use of tetracyclines over the years, common clinical pathogens have serious resistance to this product, including Gram-positive bacteria such as Staphylococcus and most Gram-negative bacilli. There is cross-resistance between this product and different varieties of tetracycline antibiotics.

In vivo, it competitively inhibits the rate-limiting enzyme hydroxymethylglutaryl coenzyme A reductase in the cholesterol synthesis process, reducing the synthesis of cholesterol and increasing the synthesis of low-density lipoprotein receptors. Its main site of action is in the liver, resulting in lower blood cholesterol and low-density lipoprotein cholesterol levels, thereby playing a role in the prevention and treatment of atherosclerosis and coronary heart disease. This product also reduces serum triglyceride levels and increases blood high-density lipoprotein levels.

This product competitively inhibits the rate-limiting enzyme hydroxymethylglutaryl coenzyme A reductase in the cholesterol synthesis process in the body, reducing the synthesis of cholesterol and increasing the synthesis of low-density lipoprotein receptors. The main site of action is in the liver, resulting in lower blood cholesterol and low-density lipoprotein cholesterol levels, thereby playing a role in the prevention and treatment of atherosclerosis and coronary heart disease. This product also reduces serum triglyceride levels and increases blood high-density lipoprotein levels.